NCT01195805

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Regional Hospital Holstebro · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

Detailed description

Purpose of the study is to examine the effect of amiloride and spironolactone on 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsewave velocity, augmentation index central bloodpressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory bloodpressure

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Spironolactone	1 tablet twice a day for 28 days
OTHER	Placebo	1 tablet twice a day for 28 days
DRUG	Amiloride	1 tablet twice a day for 28 days

Timeline

• Start date: 2010-08-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2010-09-06
• Last updated: 2015-08-20

Locations

1 site across 1 country: Denmark